Quantitative proteomic analysis of the association between decreasing O‑GlcNAcylation and metastasis in MCF‑7 breast cancer cells

Netsirisawan,Pukkavadee; Chokchaichamnankit,Daranee; Saharat,Kittirat; Srisomsap,Chantragan; Svasti,Jisnuson; Champattanachai,Voraratt

doi:10.3892/ijo.2020.5022

Quantitative proteomic analysis of the association between decreasing O‑GlcNAcylation and metastasis in MCF‑7 breast cancer cells

Authors:
- Pukkavadee Netsirisawan
- Daranee Chokchaichamnankit
- Kittirat Saharat
- Chantragan Srisomsap
- Jisnuson Svasti
- Voraratt Champattanachai
View Affiliations

Affiliations: Laboratory of Biochemistry, Chulabhorn Research Institue, Bangkok 10210, Thailand
Published online on: March 20, 2020 https://doi.org/10.3892/ijo.2020.5022
Pages: 1387-1404
Copyright: © Netsirisawan et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Breast cancer is the most common type of cancer and leading cause of cancer‑associated mortality in women worldwide. O‑linked N‑acetyl glucosaminylation (O‑GlcNAcylation) is a dynamic post‑translational modification of nuclear, cytoplasmic and mitochondrial proteins. Mounting evidence suggests that abnormal O‑GlcNAcylation status is associated with cancer malignancy. In our previous study, it was reported that O‑GlcNAc and O‑GlcNAc transferase (OGT; an enzyme responsible for the addition of O‑GlcNAc) were upregulated in breast cancer tissues and cells. Moreover, O‑GlcNAcylation was required for resistance to anoikis and the anchorage‑independent growth of breast cancer cells. However, the precise roles of this modification on the development of malignancy are yet to be elucidated. Therefore, in the present study, the effects of inhibiting O‑GlcNAc on the malignant transformation of MCF‑7 breast cancer cells under different culture conditions were determined, using monolayer (primary growth), anoikis resistance (spheroid growth) and reseeding (secondary growth) to mimic the metastatic process. Decreasing O‑GlcNAc levels using small interfering (si)RNA targeting OGT resulted in a reduction in cell viability and invasiveness in anoikis resistant and reseeding conditions. Furthermore, gel‑free quantitative proteomics was performed to identify the proteins affected by a reduction of O‑GlcNAc. A total of 317 proteins were identified and compared, and the expression of 162 proteins was altered >1.5 fold in the siOGT treated cells compared with the siScamble (siSC) treated cells. Notably, 100 proteins involved in cellular metabolism, cellular localization, stress responses and gene expression were significantly altered in the reseeding condition. Among these differentially expressed proteins, the levels of small nuclear ribonucleoprotein Sm D1 exhibited the largest decrease in expression following knockdown of OGT, and this reduction in expression was associated with a significant decrease in the levels of mTOR expression, a protein which promotes tumor growth and progression. Taken together, the results of the present study demonstrate that decreasing O‑GlcNAcylation altered protein expression, and ultimately influenced the metastatic processes, particulary regarding the invasion and reattached growth of MCF‑7 breast cancer cells.

View Figures

View References

1	Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
2	Caplan L: Delay in breast cancer: Implications for stage at diagnosis and survival. Front Public Health. 2:872014. View Article : Google Scholar : PubMed/NCBI
3	Chaffer CL and Weinberg RA: A perspective on cancer cell metastasis. Science. 331:1559–1564. 2011. View Article : Google Scholar : PubMed/NCBI
4	Valastyan S and Weinberg RA: Tumor metastasis: Molecular insights and evolving paradigms. Cell. 147:275–292. 2011. View Article : Google Scholar : PubMed/NCBI
5	Redig AJ and McAllister SS: Breast cancer as a systemic disease: A view of metastasis. J Intern Med. 274:113–126. 2013. View Article : Google Scholar : PubMed/NCBI
6	Vander Heiden MG, Cantley LC and Thompson CB: Understanding the Warburg effect: The metabolic requirements of cell proliferation. Science. 324:1029–1033. 2009. View Article : Google Scholar : PubMed/NCBI
7	Hart GW, Housley MP and Slawson C: Cycling of O-linked beta-N-acetylglucosamine on nucleocytoplasmic proteins. Nature. 446:1017–1022. 2007. View Article : Google Scholar : PubMed/NCBI
8	Kreppel LK, Blomberg MA and Hart GW: Dynamic glycosylation of nuclear and cytosolic proteins. Cloning and characterization of a unique O-GlcNAc transferase with multiple tetratricopeptide repeats. J Biol Chem. 272:9308–9315. 1997. View Article : Google Scholar : PubMed/NCBI
9	Gao Y, Wells L, Comer FI, Parker GJ and Hart GW: Dynamic O-glycosylation of nuclear and cytosolic proteins: Cloning and characterization of a neutral, cytosolic beta-N-acetylglucosa-minidase from human brain. J Biol Chem. 276:9838–9845. 2001. View Article : Google Scholar : PubMed/NCBI
10	Hanover JA, Chen W and Bond MR: O-GlcNAc in cancer: An Oncometabolism-fueled vicious cycle. J Bioenerg Biomembr. 50:155–173. 2018. View Article : Google Scholar : PubMed/NCBI
11	Chaiyawat P, Netsirisawan P, Svasti J and Champattanachai V: Aberrant O-GIcNAcylated proteins: New perspectives in breast and colorectal cancer. Front Endocrinol (Lausanne). 5:1932014. View Article : Google Scholar
12	Champattanachai V, Netsirisawan P, Chaiyawat P, Phueaouan T, Charoenwattanasatien R, Chokchaichamnankit D, Punyarit P, Srisomsap C and Svasti J: Proteomic analysis and abrogated expression of O-GlcNAcylated proteins associated with primary breast cancer. Proteomics. 13:2088–2099. 2013. View Article : Google Scholar : PubMed/NCBI
13	Phueaouan T, Chaiyawat P, Netsirisawan P, Chokchaichamnankit D, Punyarit P, Srisomsap C, Svasti J and Champattanachai V: Aberrant O-GlcNAc-modified proteins expressed in primary colorectal cancer. Oncol Rep. 30:2929–2936. 2013. View Article : Google Scholar : PubMed/NCBI
14	Netsirisawan P, Chaiyawat P, Chokchaichamnankit D, Lirdprapamongkol K, Srisomsap C, Svasti J and Champattanachai V: Decreasing O-GlcNAcylation affects the malignant transformation of MCF-7 cells via Hsp27 expression and its O-GlcNAc modification. Oncol Rep. 40:2193–2205. 2018.PubMed/NCBI
15	Khongmanee A, Lirdprapamongkol K, Tit-oon P, Chokchaichamnankit D, Svasti J and Srisomsap C: Proteomic analysis reveals important role of 14-3-3sigma in anoikis resistance of cholangiocarcinoma cells. Proteomics. 13:3157–3166. 2013. View Article : Google Scholar : PubMed/NCBI
16	Lirdprapamongkol K, Sakurai H, Kawasaki N, Choo MK, Saitoh Y, Aozuka Y, Singhirunnusorn P, Ruchirawat S, Svasti J and Saiki I: Vanillin suppresses in vitro invasion and in vivo metastasis of mouse breast cancer cells. Eur J Pharm Sci. 25:57–65. 2005. View Article : Google Scholar : PubMed/NCBI
17	Tit-Oon P, Chokchaichamnankit D, Khongmanee A, Sawangareetrakul P, Svasti J and Srisomsap C: Comparative secretome analysis of cholangiocarcinoma cell line in three-dimensional culture. Int J Oncol. 45:2108–2116. 2014. View Article : Google Scholar : PubMed/NCBI
18	Gasteiger E, Gattiker A, Hoogland C, Ivanyi I, Appel RD and Bairoch A: ExPASy: The proteomics server for in-depth protein knowledge and analysis. Nucleic Acids Res. 31:3784–3788. 2003. View Article : Google Scholar : PubMed/NCBI
19	Kall L, Canterbury JD, Weston J, Noble WS and MacCoss MJ: Semi-supervised learning for peptide identification from shotgun proteomics datasets. Nat Methods. 4:923–925. 2007. View Article : Google Scholar : PubMed/NCBI
20	O'Donnell N, Zachara NE, Hart GW and Marth JD: Ogt-dependent X-chromosome-linked protein glycosylation is a requisite modification in somatic cell function and embryo viability. Mol Cell Biol. 24:1680–1690. 2004. View Article : Google Scholar : PubMed/NCBI
21	Gu Y, Mi W, Ge Y, Liu H, Fan Q, Han C, Yang J, Han F, Lu X and Yu W: GlcNAcylation plays an essential role in breast cancer metastasis. Cancer Res. 70:6344–6351. 2010. View Article : Google Scholar : PubMed/NCBI
22	Lynch TP, Ferrer CM, Jackson SR, Shahriari KS, Vosseller K and Reginato MJ: Critical role of O-Linked beta-N-acetylglu-cosamine transferase in prostate cancer invasion, angiogenesis, and metastasis. J Biol Chem. 287:11070–11081. 2012. View Article : Google Scholar : PubMed/NCBI
23	Niu Y, Xia Y, Wang J and Shi X: O-GlcNAcylation promotes migration and invasion in human ovarian cancer cells via the RhoA/ROCK/MLC pathway. Mol Med Rep. 15:2083–2089. 2017. View Article : Google Scholar : PubMed/NCBI
24	Jiang M, Xu B, Li X, Shang Y, Chu Y, Wang W, Chen D, Wu N, Hu S, Zhang S, et al: O-GlcNAcylation promotes colorectal cancer metastasis via the miR-101-O-GlcNAc/EZH2 regulatory feedback circuit. Oncogene. 38:301–316. 2019. View Article : Google Scholar :
25	Liu Q, Zhang H, Jiang X, Qian C, Liu Z and Luo D: Factors involved in cancer metastasis: A better understanding to 'seed and soil' hypothesis. Mol Cancer. 16:1762017. View Article : Google Scholar
26	Kim YN, Koo KH, Sung JY, Yun UJ and Kim H: Anoikis resistance: An essential prerequisite for tumor metastasis. Int J Cell Biol. 2012:3068792012. View Article : Google Scholar : PubMed/NCBI
27	Choi HS, Choi BY, Cho YY, Mizuno H, Kang BS, Bode AM and Dong Z: Phosphorylation of histone H3 at serine 10 is indispensable for neoplastic cell transformation. Cancer Res. 65:5818–5827. 2005. View Article : Google Scholar : PubMed/NCBI
28	Fong JJ, Nguyen BL, Bridger R, Medrano EE, Wells L, Pan S and Sifers RN: β-N-Acetylglucosamine (O-GlcNAc) is a novel regulator of mitosis-specific phosphorylations on histone H3. J Biol Chem. 287:12195–12203. 2012. View Article : Google Scholar : PubMed/NCBI
29	Phoomak C, Park D, Silsirivanit A, Sawanyawisuth K, Vaeteewoottacharn K, Detarya M, Wongkham C, Lebrilla CB and Wongkham S: O-GlcNAc-induced nuclear translocation of hnRNP-K is associated with progression and metastasis of chol-angiocarcinoma. Mol Oncol. 13:338–357. 2019. View Article : Google Scholar :
30	Wong JCT, Hasan MR, Rahman M, Yu AC, Chan SK, Schaeffer DF, Kennecke HF, Lim HJ, Owen D and Tai IT: Nucleophosmin 1, upregulated in adenomas and cancers of the colon, inhibits p53-mediated cellular senescence. Int J Cancer. 133:1567–1577. 2013. View Article : Google Scholar : PubMed/NCBI
31	Zeng D, Xiao YS, Zhu JL, Peng CY, Liang W and Lin HY: Knockdown of nucleophosmin 1 suppresses proliferation of triple-negative breast cancer cells through activating CDH1/Skp2/p27kip1 pathway. Cancer Manag Res. 11:143–156. 2019. View Article : Google Scholar : PubMed/NCBI
32	Qin FX, Shao HY, Chen XC, Tan S, Zhang HJ, Miao ZY, Wang L, Hui-Chen and Zhang L: Knockdown of NPM1 by RNA interference inhibits cells proliferation and induces apoptosis in leukemic cell line. Int J Med Sci. 8:287–294. 2011. View Article : Google Scholar : PubMed/NCBI
33	Kazemi Z, Chang HN, Haserodt S, McKen C and Zachara NE: O-linked beta-N-acetylglucosamine (O-GlcNAc) regulates stress-induced heat shock protein expression in a GSK-3beta-dependent manner. J Biol Chem. 285:39096–39107. 2010. View Article : Google Scholar : PubMed/NCBI
34	Hung CS, Huang CY, Lee CH, Chen WY, Huang MT, Wei PL and Chang YJ: IGFBP2 plays an important role in heat shock protein 27-mediated cancer progression and metastasis. Oncotarget. 8:54978–54992. 2017. View Article : Google Scholar : PubMed/NCBI
35	Cordonnier T, Bishop JL, Shiota M, Nip KM, Thaper D, Vahid S, Heroux D, Gleave M and Zoubeidi A: Hsp27 regulates EGF/β-catenin mediated epithelial to mesenchymal transition in prostate cancer. Int J Cancer. 136:E496–E507. 2015. View Article : Google Scholar
36	Gibert B, Eckel B, Gonin V, Goldschneider D, Fombonne J, Deux B, Mehlen P, Arrigo AP, Clézardin P and Diaz-Latoud C: Targeting heat shock protein 27 (HspB1) interferes with bone metastasis and tumour formation in vivo. Brit J Cancer. 107:63–70. 2012. View Article : Google Scholar : PubMed/NCBI
37	Xiong XP, Vogler G, Kurthkoti K, Samsonova A and Zhou R: SmD1 modulates the miRNA pathway independently of its pre-mrna splicing function. PLoS Genet. 11:e10054752015. View Article : Google Scholar : PubMed/NCBI
38	Li Z and Pützer BM: Spliceosomal protein E regulates neoplastic cell growth by modulating expression of cyclin E/CDK2 and G2/M checkpoint proteins. J Cell Mol Med. 12:2427–2438. 2008. View Article : Google Scholar : PubMed/NCBI
39	Kim YD, Lee J, Kim HS, Lee MO, Son MY, Yoo CH, Choi JK, Lee SC and Cho YS: The unique spliceosome signature of human pluripotent stem cells is mediated by SNRPA1, SNRPD1, and PNN. Stem Cell Res. 22:43–53. 2017. View Article : Google Scholar : PubMed/NCBI
40	Quidville V, Alsafadi S, Goubar A, Commo F, Scott V, Pioche-Durieu C, Girault I, Baconnais S, Le Cam E, Lazar V, et al: Targeting the deregulated spliceosome core machinery in cancer cells triggers mTOR blockade and autophagy. Cancer Res. 73:2247–2258. 2013. View Article : Google Scholar : PubMed/NCBI
41	Hare SH and Harvey AJ: mTOR function and therapeutic targeting in breast cancer. Am J Cancer Res. 7:383–404. 2017.PubMed/NCBI
42	Xu K, Liu P and Wei W: mTOR signaling in tumorigenesis. Biochim Biophys Acta. 1846:638–654. 2014.PubMed/NCBI
43	Tian T, Li X and Zhang J: mTOR signaling in cancer and mTOR inhibitors in solid tumor targeting therapy. Int J Mol Sci. 20:E7552019. View Article : Google Scholar : PubMed/NCBI
44	Malaguti P, Vari S, Cognetti F and Fabi A: The Mammalian target of rapamycin inhibitors in breast cancer: Current evidence and future directions. Anticancer Res. 33:21–28. 2013.
45	Liu J, Li HQ, Zhou FX, Yu JW, Sun L and Han ZH: Targeting the mTOR pathway in breast cancer. Tumour Biol. 39:10104283177108252017. View Article : Google Scholar : PubMed/NCBI
46	Zaytseva YY, Valentino JD, Gulhati P and Evers BM: mTOR inhibitors in cancer therapy. Cancer Lett. 319:1–7. 2012. View Article : Google Scholar : PubMed/NCBI
47	Gomez-Pinillos A and Ferrari AC: mTOR signaling pathway and mTOR inhibitors in cancer therapy. Hematol Oncol Clin North Am. 26:483–505. vii2012. View Article : Google Scholar : PubMed/NCBI
48	Pópulo H, Lopes JM and Soares P: The mTOR signalling pathway in human cancer. Int J Mol Sci. 13:1886–1918. 2012. View Article : Google Scholar : PubMed/NCBI